Clinical Trials Sponsored by Pharmaxis

Total 129 results

Pharmaxis

Completed

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

Cystic Fibrosis

United States, Spain, Israel, Belgium, Czechia, South Africa, Italy, Mexico, Argentina, Australia, Canada, Hungary, New Zealand, Poland, Romania, Russian Federation, Slovakia, Ukraine
Pharmaxis

Completed

A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males

Pharmacokinetics

Australia
Pharmaxis

Completed

Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD

Lung Diseases, Obstructive

Australia
Pharmaxis

Completed

Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma

Asthma

Canada
Pharmaxis

Withdrawn

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers

Chronic Obstructive Pulmonary Disease
Pharmaxis

Withdrawn

A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma

Asthma
Pharmaxis

Completed

Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study

Cystic Fibrosis

Ireland, United Kingdom, Australia
Pharmaxis

Completed

High Dose Inhaled Mannitol Study

Bronchiectasis

Australia
Pharmaxis

Completed

Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients (DPM-PK-102)

Cystic Fibrosis

Australia, United Kingdom
Pharmaxis

Completed

Mannitol Dose Response Study in Cystic Fibrosis

Cystic Fibrosis

Canada, Argentina
Pharmaxis

Recruiting

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

REM Sleep Behavior Disorder

Australia, United Kingdom
Pharmaxis

Withdrawn

A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD

COPD | Exacerbation

Australia
Pharmaxis

Completed

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

Bronchiectasis

United States, United Kingdom, Australia, New Zealand, Argentina, Belgium, Chile, Germany, Netherlands
Pharmaxis

Completed

Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years

Cystic Fibrosis

United Kingdom
Pharmaxis

Completed

Efficacy of TPI ASM8 During a 14-Day Allergen Challenge

Asthma

Canada
Pharmaxis

Terminated

Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients

Asthma

Canada
Pharmaxis

Completed

Multiple Dose ASM8 in Mild Asthmatics

Asthma

Canada
Pharmaxis

Completed

A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device

Healthy | Bronchiectasis

Australia
Pharmaxis

Completed

Cystic Fibrosis (CF) Flow Rates Study

Cystic Fibrosis
Pharmaxis

Completed

Inspiratory Flow and Volumes in Bronchiectatics

Bronchiectasis

Australia
Pharmaxis

Completed

Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma

Asthma

Canada
Pharmaxis

Completed

Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

Copd Bronchitis

Canada
Pharmaxis

Completed

A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Cystic Fibrosis

Australia, New Zealand
Pharmaxis

Completed

Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Pharmaxis

Completed

Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

Asthma

United States
Pharmaxis

Completed

Safety and Efficacy of Bronchitol in Bronchiectasis

Bronchiectasis

Australia, New Zealand, United Kingdom
Pharmaxis

Completed

Inspiratory Flow Using the Osmohaler

Asthma
Pharmaxis

Completed

A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects

Healthy Volunteers
Pharmaxis
i3 Research

Completed

Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma

Allergic Asthma

United Kingdom
PharmaIN

Recruiting

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

Cirrhosis, Liver | Liver Fibrosis | Ascites Hepatic

United States
PharmaBio Corporation

Recruiting

Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

Myopic Chorioretinal Atrophy

Japan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
Planexta, Inc
Pharmaxi LLC

Completed

Measuring Accuracy of Wristband for Registration of ECG RR-Intervals for One Hand, SenceBand in Comparison to Holter

HRV

Ukraine
McMaster University
Pharmaxis; AllerGen NCE Inc.

Completed

Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma (MICC)

Cough | Asthma

Canada
Pharvaris Netherlands B.V.

Recruiting

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (RAPIDe-3)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
Phraxis, Inc.

Completed

Continued Access Study VIG Anastomotic Connector (VIG-CAS)

Dialysis Access Malfunction

United States
Centre Hospitalier Universitaire de Saint Etienne
Pharmaxis

Completed

Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough (MANOTOUX)

Cough | Bronchial Hyperreactivity

France
Pharvaris Netherlands B.V.

Recruiting

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-2)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
Phraxis, Inc.

Completed

Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]

End Stage Renal Disease

United States
Hannover Medical School
Pharmacia

Completed

L-Arginine and Erectile Dysfunction

Erectile Dysfunction

Germany
Pure Purr LLC
Pharmaxi LLC

Completed

Study of the Effect of the VR Technology on Recovery of the Autonomic Nervous System in Volunteers Affected by Stress

Stress

Ukraine
Sankom SA
InterMedService SA; Pharmaxi LLC

Unknown

Study to Evaluate Impact SANKOM Patent Socks in Patients With CVI

Chronic Venous Insufficiency

Ukraine
University of Lausanne
Pharmacia

Completed

Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit (SUNIC)

Smoking Cessation

Switzerland
Hannover Medical School
Pharmacia

Completed

Effects of Growth Hormone on the Nitric Oxide Pathway

Cardiovascular Disease

Germany
Eisai Inc.
PharmaBio Development Inc.

Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Ovarian Cancer

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Belgium, Italy, Spain, United States, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine

Clinical Trials Sponsored by Pharmaxis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations